SINGLE–CENTER ANALYSIS OF A POPULATION OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS TREATED WITH TAFAMIDIS: OUTCOMES AND IMPACT ON DISEASE PROGRESSION

Abstract

Introduction

Tafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR–CM); however, validated criteria for monitoring disease progression in treated patients are still lacking. Emerging evidence from untreated cohorts suggests that increases in NT–proBNP levels and outpatient diuretic intensification (ODI) may represent markers of progression.

Objectives

To evaluate all–cause mortality and cardiovascular hospitalizations in a real–world population of NYHA class I–II ATTR–CM patients treated with tafamidis; to assess the frequency of disease progression markers; and to identify those associated with an unfavourable prognosis.